Last reviewed · How we verify
NCT03770169
Validation of Patient Reported Outcome Measures for Use in Vulvodynia
trial in Vulvodynia in 20 participants. Completed in 19 September 2019.
19 September 2019
Quick facts
| Lead sponsor | Ipsen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 18 February 2019 |
| Primary completion | 19 September 2019 |
| Estimated completion | 19 September 2019 |
| Sites | 4 locations across United States |
Conditions studied
- Vulvodynia — all drugs for Vulvodynia →
Sponsor
Ipsen — full company profile →
Who can join
Adults 18 to 45, female only, with Vulvodynia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall aim of this project is to demonstrate content validity and usability of the modified Vulvar Pain Assessment Questionnaire (mVPAQ), the modified Female Sexual Function Index (mFSFI), and pain on intercourse Numeric Rating Scale (NRS) for adult patients with Vulvodynia
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03770169
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vulvodynia
Currently open trials in the same condition.
- NCT07257029 — Topical Ketotifen 0.25% for Secondary Vestibulodynia · Phase 2 · recruiting
- NCT07391241 — A Phase 2 Study to Evaluate the Efficacy and Safety of Pudafensine in Vulvodynia (Provoked Vestibulodynia) · Phase 2 · recruiting
- NCT07092332 — Young Vulvodynia: Effect and Efficacy of Multimodal Treatment. · NA · recruiting
- NCT06865963 — Vestibulodynia At High Resolution: Omics Approach to Improve Diagnosis · recruiting
- NCT05955313 — Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia · Phase 2 · recruiting
Other Ipsen trials
Trials by the same sponsor.
- NCT07387549 — A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis · Phase 3 · not yet recruiting
- NCT07497724 — Retrospective Observational Study of Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-P · not yet recruiting
- NCT07427797 — A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between · Phase 3 · recruiting
- NCT07435428 — A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Line · Phase 3 · recruiting
- NCT07441707 — A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03770169 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ipsen
- Last refreshed: 28 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03770169.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing